Anavex Life Sciences (NASDAQ:AVXL) Given Buy Rating at HC Wainwright

HC Wainwright reissued their buy rating on shares of Anavex Life Sciences (NASDAQ:AVXL) in a report published on Monday,Benzinga reports. The firm currently has a $42.00 price target on the biotechnology company’s stock.

Separately, D. Boral Capital restated a “buy” rating and issued a $46.00 price objective on shares of Anavex Life Sciences in a research report on Wednesday, February 12th.

Anavex Life Sciences Stock Down 1.6 %

Anavex Life Sciences stock opened at $8.58 on Monday. The company has a market capitalization of $729.85 million, a P/E ratio of -15.60 and a beta of 0.94. The firm has a 50 day moving average price of $8.99 and a 200-day moving average price of $8.35. Anavex Life Sciences has a twelve month low of $3.25 and a twelve month high of $14.44.

Anavex Life Sciences (NASDAQ:AVXL) last posted its earnings results on Wednesday, February 12th. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.17) by $0.03. Equities analysts expect that Anavex Life Sciences will post -0.69 EPS for the current fiscal year.

Institutional Trading of Anavex Life Sciences

A number of hedge funds have recently made changes to their positions in AVXL. Barclays PLC increased its stake in Anavex Life Sciences by 70.4% in the third quarter. Barclays PLC now owns 155,179 shares of the biotechnology company’s stock valued at $882,000 after acquiring an additional 64,101 shares during the last quarter. Y Intercept Hong Kong Ltd bought a new position in shares of Anavex Life Sciences during the 4th quarter valued at about $243,000. Charles Schwab Investment Management Inc. raised its holdings in shares of Anavex Life Sciences by 2.3% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 665,976 shares of the biotechnology company’s stock valued at $3,783,000 after buying an additional 14,892 shares in the last quarter. Heartland Advisors Inc. bought a new stake in Anavex Life Sciences in the 4th quarter worth approximately $1,674,000. Finally, Virtu Financial LLC purchased a new stake in Anavex Life Sciences in the fourth quarter worth approximately $967,000. 31.55% of the stock is owned by institutional investors.

Anavex Life Sciences Company Profile

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.